{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:51:49Z","timestamp":1790013109350,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01 BX002741"],"award-info":[{"award-number":["I01 BX002741"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["R21 ES029258"],"award-info":[{"award-number":["R21 ES029258"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01 GM135258"],"award-info":[{"award-number":["R01 GM135258"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.dmd.2025.100128","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T15:08:53Z","timestamp":1753456133000},"page":"100128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fibroblast growth factor 15 overexpression and combined peroxisome proliferator\u2013activated receptor \u03b1 activation attenuates metabolic dysfunction\u2013associated steatohepatitis progression in mice"],"prefix":"10.1016","volume":"53","author":[{"given":"Hong","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Stofan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-7817","authenticated-orcid":false,"given":"Bo","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rulaiha","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6272-8115","authenticated-orcid":false,"given":"Zakiyah","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda","family":"Maliha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rizzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2666-0635","authenticated-orcid":false,"given":"Grace L.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.dmd.2025.100128_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.dmd.2025.100128_bib2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.dmd.2025.100128_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100128_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/qjmed\/hcp158","article-title":"Pathogenesis of non-alcoholic fatty liver disease","volume":"103","author":"Dowman","year":"2010","journal-title":"QJM"},{"issue":"8","key":"10.1016\/j.dmd.2025.100128_bib5","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.dmd.2025.100128_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tem.2014.10.002","article-title":"Tissue-specific actions of the metabolic hormones FGF15\/19 and FGF21","volume":"26","author":"Owen","year":"2015","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.dmd.2025.100128_bib7","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.25740","article-title":"Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice","volume":"56","author":"Kong","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.dmd.2025.100128_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmet.2011.03.019","article-title":"FGF15\/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway","volume":"13","author":"Potthoff","year":"2011","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.dmd.2025.100128_bib9","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","article-title":"Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity","volume":"143","author":"Tomlinson","year":"2002","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.dmd.2025.100128_bib10","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1210\/en.2003-1671","article-title":"Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes","volume":"145","author":"Fu","year":"2004","journal-title":"Endocrinology"},{"issue":"6024","key":"10.1016\/j.dmd.2025.100128_bib11","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","article-title":"FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis","volume":"331","author":"Kir","year":"2011","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.dmd.2025.100128_bib12","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep.30810","article-title":"Direct and indirect effects of fibroblast growth factor (FGF) 15 and FGF19 on liver fibrosis development","volume":"71","author":"Schumacher","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.dmd.2025.100128_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2017.06.023","article-title":"The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis","volume":"330","author":"Schumacher","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100128_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000444","article-title":"Effects of intestine-specific deletion of FGF15 on the development of fatty liver disease with vertical sleeve gastrectomy","volume":"8","author":"Chow","year":"2024","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.dmd.2025.100128_bib15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100128_bib16","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPARalpha in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr Rev"},{"issue":"6","key":"10.1016\/j.dmd.2025.100128_bib17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.dmd.2025.100128_bib18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.dmd.2025.100128_bib19","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1111\/dom.15524","article-title":"The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis","volume":"26","author":"Abdelmalek","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.dmd.2025.100128_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100128_bib21","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/hep4.1108","article-title":"Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice","volume":"1","author":"Zhou","year":"2017","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.dmd.2025.100128_bib22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.28257","article-title":"Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice","volume":"63","author":"Zhou","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.dmd.2025.100128_bib23","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/hep.30041","article-title":"Fibroblast growth factor 15-dependent and bile acid-independent promotion of liver regeneration in mice","volume":"68","author":"Kong","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.dmd.2025.100128_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/toxsci\/kfae110","article-title":"Effects of therapeutically approved individual bile acids on the development of metabolic dysfunction-associated steatohepatitis a low bile acid mouse model","volume":"202","author":"Taylor","year":"2024","journal-title":"Toxicol Sci"},{"issue":"1","key":"10.1016\/j.dmd.2025.100128_bib25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1124\/jpet.108.144600","article-title":"Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet","volume":"328","author":"Kong","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.dmd.2025.100128_bib26","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s41374-020-0439-y","article-title":"Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency","volume":"100","author":"Huang","year":"2020","journal-title":"Lab Invest"},{"issue":"4","key":"10.1016\/j.dmd.2025.100128_bib27","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.dld.2018.12.026","article-title":"FXR deficiency alters bile acid pool composition and exacerbates chronic alcohol induced liver injury","volume":"51","author":"Kong","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.dmd.2025.100128_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2024-100074","article-title":"Bile acids regulation of cellular stress responses in liver physiology and diseases","volume":"2","author":"Li","year":"2024","journal-title":"eGastroenterology"},{"issue":"6","key":"10.1016\/j.dmd.2025.100128_bib29","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"6","author":"Vacca","year":"2024","journal-title":"Nat Metab"},{"issue":"6","key":"10.1016\/j.dmd.2025.100128_bib30","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1210\/en.2007-0014","article-title":"Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation","volume":"148","author":"Stienstra","year":"2007","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.dmd.2025.100128_bib31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1440-1746.2011.06939.x","article-title":"Peroxisome proliferator-activated receptor-alpha agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis","volume":"27","author":"Larter","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100128_bib32","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3945\/jn.110.135210","article-title":"PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver","volume":"141","author":"Abdelmegeed","year":"2011","journal-title":"J Nutr"},{"issue":"1","key":"10.1016\/j.dmd.2025.100128_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/hep.32538","article-title":"Intestinal peroxisome proliferator-activated receptor alpha-fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis","volume":"77","author":"Yan","year":"2023","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.dmd.2025.100128_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006796","article-title":"Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human","volume":"4","author":"Rakhshandehroo","year":"2009","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.dmd.2025.100128_bib35","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0168-8278(99)80243-8","article-title":"A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis","volume":"31","author":"Basaranoglu","year":"1999","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100128_bib36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc3214","article-title":"The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention","volume":"12","author":"Peters","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.dmd.2025.100128_bib37","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/jgh3.12650","article-title":"Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score","volume":"5","author":"Hatanaka","year":"2021","journal-title":"JGH Open"},{"issue":"3","key":"10.1016\/j.dmd.2025.100128_bib38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","article-title":"A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease","volume":"40","author":"Fern\u00e1ndez-Miranda","year":"2008","journal-title":"Dig Liver Dis"},{"issue":"10","key":"10.1016\/j.dmd.2025.100128_bib39","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2025.100128_bib40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cmet.2008.06.014","article-title":"The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man","volume":"8","author":"Galman","year":"2008","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.dmd.2025.100128_bib41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.bbrc.2007.06.068","article-title":"PPARalpha is a key regulator of hepatic FGF21","volume":"360","author":"Lund\u00e5sen","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.dmd.2025.100128_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8416763","article-title":"Oxidative stress: harms and benefits for human health","volume":"2017","author":"Pizzino","year":"2017","journal-title":"Oxid Med Cell Longev"},{"issue":"12","key":"10.1016\/j.dmd.2025.100128_bib43","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1124\/dmd.110.035006","article-title":"Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease","volume":"38","author":"Hardwick","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2025.100128_bib44","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.freeradbiomed.2004.02.074","article-title":"Nrf2 signaling in coordinated activation of antioxidant gene expression","volume":"36","author":"Jaiswal","year":"2004","journal-title":"Free Radic Biol Med"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:21:00Z","timestamp":1778714460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625091378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0090955625091378"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100128","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibroblast growth factor 15 overexpression and combined peroxisome proliferator\u2013activated receptor \u03b1 activation attenuates metabolic dysfunction\u2013associated steatohepatitis progression in mice","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100128"}}